SENAZODAN manufacturers
- Senazodan
-
- $1520.00
-
2026-05-11
- CAS:98326-32-0
- Purity:
- Supply Ability: 10g
- Senazodan
-
- $1520.00
-
2026-01-05
- CAS:98326-32-0
- Purity:
- Supply Ability: 10g
|
| | SENAZODAN Basic information |
| Product Name: | SENAZODAN | | Synonyms: | SENAZODAN;3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(4-pyridinylamino)phenyl)-;6-(4-(4-Pyridinylamino)phenyl)-4,5-dihydro-3(2H)-pyridazinone;3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1H-pyridazin-6-one;Unii-427L2I2kim | | CAS: | 98326-32-0 | | MF: | C15H14N4O | | MW: | 266.3 | | EINECS: | | | Product Categories: | | | Mol File: | 98326-32-0.mol |  |
| | SENAZODAN Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | SENAZODAN Usage And Synthesis |
| Uses | Senazodan (MCI 154) is a Ca2+ sensitiser, and also shows inhibition effect on PDE III[1][2]. | | in vivo | Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) decreases the pressor effect of norepinephrine (NE)[3].
Senazodan (0.1 mg/kg; i.v.) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably[4]. | Animal Model: | Wistar rats (200~250 g)[3] | | Dosage: | 0.1~2.0 mg/kg | | Administration: | Left femoral vein catheterization infusion | | Result: | Decreased the pressor effect of norepinephrine (NE).
|
| Animal Model: | Rabbits[4] | | Dosage: | 0.1 mg/kg | | Administration: | I.v. | | Result: | LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.
|
| | References | [1] Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203. DOI:10.2165/00003088-200443030-00003
[2] Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70. DOI:10.1517/13543784.14.6.659
[3] Yang G, et al. Effects of MCI-154 on vascular reactivity and its mechanisms after hemorrhagic shock in rats. J Cardiovasc Pharmacol. 2006;47(6):751-757. DOI:10.1097/01.fjc.0000211790.14787.e7
[4] Ming MJ, et al. Effects of MCI-154, a calcium sensitizer, on cardiac dysfunction in endotoxic shock in rabbits. Shock. 2000;13(6):459-463. DOI:10.1097/00024382-200006000-00007 |
| | SENAZODAN Preparation Products And Raw materials |
|